Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its ...

Novartis’ anti-IgE antibody Xolair (omalizumab) has been a mainstay of treatment for refractory CSU for many years. However, ...

COVID-19 vaccination rates have fallen precipitously in Europe and should be ramped up this autumn so they are at least in ...

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular ...

Approval by the European Commission generally follows a few weeks after a CHMP decision, and that situation contrasts with ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial ...

At the ASCO congress in Chicago today, the results of the ASC4FIRST trial of Scemblix (asciminib) in people recently ...

The US Senate has joined the House of Representatives in approving the first-ever federal bill dedicated to ending ...

Elliot Pfebve (55) received the experimental vaccine at University Hospitals Birmingham NHS Foundation Trust, one of several ...

The FDA sent the Japanese pharma a complete response letter (CRL) in January saying it was unable to approve zolbetuximab as ...

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal ...

Akili went public via a merger with a special purpose acquisition company (SPAC) in 2022 that raised around $163 million and ...